ATTACK ON NUCLEOPROTEIN IN CLINICAL CANCER CHEMOTHERAPY.
D000818:Animals; D000963:Antimetabolites; D000970:Antineoplastic Agents; D001152:Arsenicals; D035843:Biomedical Research; D002286:Carcinoma, Ehrlich Tumor; D004342:Drug Hypersensitivity; D004358:Drug Therapy; D006651:Histocytochemistry; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009698:Nucleoproteins; D010600:Pharmacology; D013438:Sulfhydryl Compounds
D000963:Antimetabolites; D000970:Antineoplastic Agents; D001152:Arsenicals; D009698:Nucleoproteins; D013438:Sulfhydryl Compounds; C100059:oxophenarsine
ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CLINICAL RESEARCH; DRUG HYPERSENSITIVITY; DRUG THERAPY; HISTOCYTOCHEMISTRY; MICE; NEOPLASM THERAPY; NUCLEOPROTEINS; OXOPHENARSINE; PHARMACOLOGY; SULFHYDRYL COMPOUNDS